4-Letter Word: FDA's Biosimilars/Biologics Distinction
This article was originally published in Scrip
Executive Summary
The FDA wants all biologics, including biosimilars, to carry a unique four-letter suffix as part of the nonproprietary names (INNs) of the active drug substance, the agency revealed on Aug. 27 in a draft guidance document and a proposed rule – giving a big win to innovator manufacturers, which have insisted on imposing distinguishable names on the copycats.